LGG-06. Selumetinib in pediatric patients with non-neurofibromatosis type 1-associated, non-optic pathway (OPG) and non-pilocytic recurrent/progressive low-grade glioma harboring BRAFV600E mutation or BRAF-KIAA1549 fusion: a multicenter prospective Pediatric Brain Tumor Consortium (PBTC) Phase 2 trial

BACKGROUND: A greater understanding of the Ras-MAP kinase pathway in pediatric low-grade glioma (LGG) paired with the availability of selective inhibitors has enhanced the ability to target this pathway with therapeutic intent. METHODS: The PBTC conducted a multi-institutional phase II study (NCT010...

Descripción completa

Detalles Bibliográficos
Autores principales: Fangusaro, Jason, Onar-Thomas, Arzu, Poussaint, Tina Young, Lensing, Shelly, Wu, Shengjie, Ligon, Azra H, Lindeman, Neal, Stewart, Clinton F, Jones, David T W, Pfister, Stefan M, Smiley, Natasha Pillay, Leach, James, Packer, Roger, Vezina, Gilbert, Lenzen, Alicia, Jaju, Alok, Goldman, Stewart, Doyle, Laurence Austin, Smith, Malcolm, Fouladi, Maryam, Dunkel, Ira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Low Grade Glioma
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164871/
http://dx.doi.org/10.1093/neuonc/noac079.322

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164871/
http://dx.doi.org/10.1093/neuonc/noac079.322

Ejemplares similares